Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 1, 1997, Pages 37-48

  Einspahr, Janine G ^a   Alberts, David S ^a   Gapstur, Susan M ^c   Bostick, Roberd M ^b   Emerson, Scott S ^d   Gerner, Eugene W ^a,e  

^a UNIVERSITY OF ARIZONA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

APOPTOSIS; ARACHIDONIC ACID METABOLISM; CANCER GENETICS; CANCER RISK; CELL PROLIFERATION; COLON CANCER; HUMAN; POLYAMINE METABOLISM; PRECANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

APOPTOSIS; ARACHIDONIC ACID; CHEMOPREVENTION; COLONIC NEOPLASMS; HUMANS; MITOTIC INDEX; MUTATION; POLYAMINES; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031023574     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer Statistics. CA Cancer J. Clin., 44: 7-26, 1994.
2. Morson, B. President's address. The polyp-cancer sequence in the large bowel. Proc. R. Soc. Med., 67: 451-457, 1974.
3. Kelloff, G. J., Boone, C. W., Steele, V. E., Crowell, J. A., Lubet, R., and Sigman, C. C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 54 (Suppl.): 2015s-2024s, 1994.
4. Schatzkin, A., Freedman, L. S., Schiffman, M. H., and Dawsey, S. M. Validation of intermediate end points in cancer research. J. Natl. Cancer Inst., 82: 1746-1752, 1990.
5. Schatzkin, A., Freedman, L., and Schiffman, M. An epidemiologic perspective on biomarkers. J. Intern. Med., 233: 75-79, 1993.
6. Perera, F. P., and Whyatt, R. M. Biomarkers and molecular epidemiology in mutation/cancer research. Mutat. Res., 313: 117-129, 1994.
7. Rothman, N., Steward, W. F., and Schulte, P. A. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epidemiol, Biomarkers & Prev., 4: 301-311, 1995.
8. Lippman, S. M., Lee, J. S., Lotan, R., Hittelman, W., Wargovich, M. J., and Hong, W. K. Biomarkers as intermediate end points in chemoprevention trials. J. Natl. Cancer Inst., 82: 555-560, 1990.
9. Boone, C. W., Kelloff, G. J., and Steele, V. E. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res., 52: 1651-1659, 1992.
10. Earnest, D. L., Hixson, L. J., and Alberts, D. S. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. Cell. Biochem., 161: 156-166, 1992.
11. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
12. Pasricha, P. J., Bedi, A., O'Conner, K., Rashid, A., Akhtar, A. J., Zahurak, M. L., Piatadosi, S., Hamilton, S. R., and Giardiello, F. M. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology, 109: 994-998, 1995.
13. O'Brien, M. J., O'Keane, C. J., Zauber, A., Gottlieb, L. S., and Winawer, S. J. Precursors of colorectal carcinoma. Cancer (Phila.), 70: 1317-1327, 1992.
14. Scalamati, A., and Lipkin, M. Proliferation and differentiation biomarkers in colorectal mucosa and their application to chemoprevention. Environ. Health Perspect., 99: 169-173, 1993.
15. Bleiberg, H., Buyse, M., and Garland, P. Cell kinetic indicators of premalignant stages of colorectal cancer. Cancer (Phila.), 56: 124-129, 1985.